Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae417 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Jing Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Pharmacovigilance, Product Surveillance, Postmarketing, Graves Ophthalmopathy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Context
Teprotumumab, which targets the insulin-like growth factor-1 receptor, is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease (TED).
Objective
This study aimed to identify potential safety signals of teprotumumab by analyzing postmarketing safety data from the FDA Adverse Event Reporting System (FAERS) database in 2023.
Methods
The case/noncase approach was used to estimate the reporting odds ratio (ROR) and information component (IC) with relevant 95% CI for adverse events (AEs) that numbered 3 or more.
Results
A total of 2158 cases were included in the analysis. Main safety signals identified were ear and labyrinth disorders, reproductive system and breast disorders, metabolism and nutrition disorders, and gastrointestinal disorders. Specifically, autophony (ROR [95% CI] = 4188.34 [1403.29-12500.8]), eyelid retraction (ROR [95% CI] = 2094.17 [850.69-5155.29]), permanent deafness (ROR [95% CI] = 1552.35 [789.07-3053.98]), bilateral deafness (ROR [95% CI] = 73.12 [41.14-129.97]), inflammatory bowel disease (ROR [95% CI] = 23.26 [13.46-40.19]), hyperglycemic hyperosmolar nonketotic syndrome (ROR [95% CI] = 17.75 [5.70-55.28]), and amenorrhea (ROR [95% CI] = 47.98 [36.22-63.54]) showed significant safety signals with teprotumumab.
Conclusion
This study identified ear and labyrinth disorders, and reproductive system and breast disorders, as specific safety signals of teprotumumab. Clinicians and pharmacists should be vigilant regarding these AEs. However, available data are currently insufficient, and further pharmacovigilance and surveillance are needed to fully understand this issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen 361005, China.
ORCID-Profile: Jing Huang, Wei Zhuang, Zhihui Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, J., Su, A., Yang, J., Zhuang, W., & Li, Z. (2024). Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae417
Vancouver
Huang J, Su A, Yang J, Zhuang W, Li Z. Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae417
BibTeX
@article{Huang2024,
author = {Huang, Jing and Su, Anping and Yang, Jing and Zhuang, Wei and Li, Zhihui},
title = {Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae417}
}
EUVIMED